YM-155 Hydrochloride: Potent Survivin Inhibitor for Advanced Cancer Research

Executive Summary: YM-155 hydrochloride (A3947, APExBIO) is a potent small-molecule survivin inhibitor with an IC50 of 0.54 nM for human survivin, enabling highly selective suppression of the IAP pathway in vitro and in vivo (APExBIO). The compound induces tumor regression in diverse xenograft models, including NSCLC and triple-negative breast cancer, with minimal off-target effects on other IAP or BCL-2 family proteins (Schwartz 2022). YM-155 hydrochloride is soluble in DMSO (≥19.45 mg/mL), ethanol (≥4.34 mg/mL), and water (≥48.1 mg/mL) under specified conditions, and requires storage at -20°C to maintain stability. Recent in vitro and systems biology studies have established robust protocols for evaluating drug responses using fractional viability and proliferation assays (Schwartz 2022). This article details the biological rationale, mechanism, and evidence base for deploying YM-155 hydrochloride as a selective apoptosis pathway inhibitor in advanced cancer research.

Biological Rationale

Survivin (BIRC5), the smallest member of the inhibitor of apoptosis protein (IAP) family, is overexpressed in most human cancers but is nearly undetectable in differentiated adult tissues (Schwartz 2022). Survivin supports cell cycle progression and suppresses apoptosis, conferring resistance to chemotherapeutics and promoting tumor survival. Targeting survivin disrupts cell division and sensitizes cancer cells to apoptosis. Inhibiting the IAP pathway is a validated strategy for inducing selective tumor cell death while sparing normal tissues. YM-155 hydrochloride was developed to exploit this unique tumor dependency on survivin, enabling precise cancer cell targeting (see also PD-L1.com).

Mechanism of Action of YM-155 hydrochloride

YM-155 hydrochloride acts as a potent, selective small-molecule inhibitor of survivin transcription. The compound binds to the promoter region of the BIRC5 gene, thereby suppressing survivin mRNA and protein expression (Schwartz 2022). This suppression triggers apoptosis via caspase activation and disrupts mitotic spindle formation, leading to mitotic arrest and cell death. YM-155 hydrochloride does not significantly inhibit other IAPs or BCL-2 family proteins at concentrations effective against survivin (APExBIO). The compound’s nanomolar potency (IC50 = 0.54 nM) enables robust suppression of survivin signaling with minimal off-target effects.

Evidence & Benchmarks

• YM-155 hydrochloride inhibits survivin with an IC50 of 0.54 nM in cell-based transcriptional reporter assays (APExBIO).
• Selective for survivin: negligible activity against other IAP family members (XIAP, cIAP1, cIAP2) or BCL-2 proteins at concentrations up to 100 nM (Schwartz 2022).
• Suppresses proliferation in >20 human cancer cell lines across tissue origins, including NSCLC, melanoma, bladder, lymphoma, and breast cancer models (Schwartz 2022).
• Induces tumor regression and reduces spontaneous metastases in xenograft models of triple-negative breast cancer (TNBC) at 5–10 mg/kg dosed daily, with significant survival extension (see Table 3 in Schwartz 2022).
• Solubility: ≥19.45 mg/mL in DMSO, ≥4.34 mg/mL in ethanol (with gentle warming and sonication), and ≥48.1 mg/mL in water (with sonication), enabling versatile formulation (APExBIO).
• YM-155 hydrochloride has been benchmarked in in vitro protocols that distinguish between cytostatic and cytotoxic effects using fractional viability assays (Schwartz 2022).

For a systems-biology perspective and strategic guidance on deployment, see "Redefining Translational Oncology: Strategic Deployment of YM-155 Hydrochloride"; this current article provides updated, atomically referenced data and clarification on in vitro methodology.

Applications, Limits & Misconceptions

YM-155 hydrochloride is utilized in:

• Preclinical cancer research to dissect the survivin/IAP signaling pathway.
• Validation of apoptosis-inducing drug mechanisms in cell lines and xenograft models.
• Modeling tumor regression and metastasis inhibition, notably in NSCLC and TNBC.
• Benchmarking new survivin pathway inhibitors against a well-characterized reference compound.

Common Pitfalls or Misconceptions

• Not a pan-IAP inhibitor: YM-155 hydrochloride shows high selectivity for survivin and is ineffective against other IAPs or BCL-2 proteins at standard doses (Schwartz 2022).
• Not suitable for diagnostic or clinical therapeutic use: Intended for research use only; not validated for human or veterinary medicine (APExBIO).
• Requires careful solubilization: Suboptimal dissolution (e.g., in cold ethanol or water) can limit activity; always use recommended protocols (see product technical sheet).
• Instability in solution: Stock solutions are for short-term use only; avoid repeated freeze-thaw cycles to preserve activity (APExBIO).
• Cell line-dependent effects: Some non-cancerous or resistant lines may exhibit minimal response, highlighting the importance of pathway-specific context (Schwartz 2022).

For workflow-centric guidance and mechanistic precision in apoptosis assays, see "Reprogramming the Survivin Axis", which is complemented here with new, benchmarked solubility and selectivity parameters.

Workflow Integration & Parameters

YM-155 hydrochloride is supplied as a solid (C20H19ClN4O3, MW 398.84) by APExBIO (SKU: A3947). Dissolve in DMSO to ≥19.45 mg/mL for stock solutions; for aqueous applications, dissolve in water with ultrasonic treatment. For ethanol, gentle warming and sonication are required. Store all forms at -20°C and use solutions promptly, as stability is limited. Recommended concentrations for in vitro assays range from 0.5 nM to 100 nM, depending on cell type and endpoint (Schwartz 2022). To evaluate true cytotoxicity versus cytostasis, use both relative and fractional viability protocols as described in recent systems-biology studies. For best practices, consult the YM-155 hydrochloride product page and refer to "YM-155 Hydrochloride: Redefining Survivin Inhibition in Apoptosis Research", which this article updates by adding new solubility and workflow guidance.

Conclusion & Outlook

YM-155 hydrochloride is a gold-standard tool for dissecting the survivin/IAP axis in cancer research. Its nanomolar potency, selectivity, and characterized workflow parameters make it an essential reference for functional apoptosis studies, tumor regression models, and the benchmarking of novel pathway inhibitors. By adhering to robust solubilization, dosing, and viability assay protocols, researchers can maximize the reliability and translational value of YM-155 hydrochloride studies. For further strategic and translational insights, see related overviews on translational deployment of survivin inhibitors, which this article augments with updated atomic data and experimental boundaries.